Taranabant

Drug Profile

Taranabant

Alternative Names: MK-0364

Latest Information Update: 02 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Amides; Obesity therapies; Pyridines
  • Mechanism of Action Cannabinoid 1 receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Psychiatric disorders; Smoking withdrawal

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 03 Oct 2008 Discontinued - Phase-III for Obesity in USA, Australia, Austria, Czech Republic, Denmark, Finland, France, Germany, New Zealand and Sweden (PO)
  • 01 Apr 2008 Interim efficacy and adverse events data from a phase III trial in Obesity presented at the 57th Annual Scientific Session of the American College of Cardiology (ACC-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top